Year: 2020
Type: dissertation
Abstract: Atherosclerotic cardiovascular disease (ASCVD) is a disorder that affects both heart and blood vessels. It is caused by atherosclerosis, a chronic, low-grade inflammatory disease, which is characterized by the accumulation of lipids in the arterial wall. Modified lipoproteins contain pro-inflammatory epitopes, such as phosphorylcholine (PC), that interact with inflammatory cells in the vascular wall, thereby accelerating the development of atherosclerotic lesions. The main cause of myocardial infarction (MI) arises from a rupture of an unstable, inflamed atherosclerotic lesion in the coronary artery. The MI induces an intense inflammatory response that is essential for myocardial repair and scar formation, but which is also implicated in the onset of heart failure over time. Molecular imaging techniques can be potentially used for identification of new molecular targets, such as glucagon-like peptide-1 receptor (GLP-1R), that are involved in inflammatory and repair processes. The aim of this thesis was to investigate whether a novel immunotherapy targeting the PC epitope improves vascular function and attenuates atherosclerotic inflammation in mice. A positron emission tomography (PET) tracer 68Ga¬NODAGA-exendin-4 was evaluated for detection and imaging of GLP-1R expression after MI and in atherosclerosis in experimental models. In vivo PET imaging, ultrasound imaging, tissue autoradiography, immunohistological stainings, and cell assays were utilized as the main methods in the studies. This thesis showed that treatment with the PC immunotherapy preserved coronary artery function and attenuated the uptake of an established inflammation tracer, glucose analog 18F-FDG, in atherosclerotic lesions in mice. 68Ga-NODAGA¬exendin-4 PET detected up-regulated cardiac GLP-1R expression during the healing of MI in rats. The uptake of 68Ga-NODAGA-exendin-4 was also increased in inflamed atherosclerotic lesions in mice. In conclusion, PC immunotherapy might represent a potential approach to inhibit the lipid-driven inflammation in atherosclerosis. 68Ga-NODAGA-exendin-4 PET may have implications for studying pharmacological modification of GLP-1R signaling in ASCVD.
Source: UTUPub (University of Turku)
Author: Mia Ståhle
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Funders: Ida Montinin Säätiö, Itä-Suomen Yliopisto, Jalmari ja Rauha Ahokkaan Säätiö, Minerva Foundation, Universiteit van Amsterdam, Suomen Kulttuurirahasto, Turun Yliopisto, Sydäntutkimussäätiö, Sigrid Juséliuksen Säätiö, Åbo Akademi, Instrumentariumin Tiedesäätiö, Turun Yliopistollinen Keskussairaala
OpenAlex ID: W3104469728
